Researchers have investigated the impact of azacitidine (AZA) on the body's normal blood cells, particularly in patients with myelodysplastic syndromes (MDS), a group of disorders characterized by poorly formed or dysfunctional blood cells.

Azacitidine, marketed under the brand name Vidaza, is a medication approved by the US FDA to treat MDS, chronic myelomonocytic leukemia (CMML), and certain other conditions [1]. According to the medication's prescribing information and available studies, azacitidine has been shown to improve hematologic parameters, including increases in red blood cells, white blood cells, and platelet production in some patients with MDS [2].

Studies suggest that the mechanism by which azacitidine exerts its effects involves the modulation of epigenetic regulation, which leads to increased production of normal blood cells, particularly red blood cells [3]. In this context, azacitidine has been shown to increase the levels of globin gene expression, a key regulator of red blood cell production.

However, the use of azacitidine can also lead to side effects related to the suppression of normal blood cell production, including anemia, thrombocytopenia (low platelet count), and leukopenia (low white blood cell count) [4]. As with any medication, careful consideration and monitoring of a patient's blood cell count are warranted to mitigate these risks.

For individuals undergoing treatment with azacitidine, blood counts should be regularly monitored to detect any potential adverse effects on the body's normal blood cells. It is essential to consult with a healthcare provider to discuss the potential benefits and risks associated with azacitidine treatment.

Sources:

[1] FDA Approval: Vidaza (Azacitidine Injection) for Injection, for Intravenous Use - FDA (Available: https://www.fda.gov/drugs/information-drug-class/fda-approval-vidaza-azacitidine-injection-for-injection-intravenous-use accessed on 2024)

[2] Fenaux et al. (2009). Azacitidine prolongs overall survival, transformation time to acute myeloid leukemia (AML), and does not increase the development of AML or blast crisis in patients with myelodysplastic syndromes (MDS) according to published International Working Group (IWG) response criteria. Leukemia, 23(8), 1553-1556.

[3] Silverman LH, et al. (2010). Effects of Azacitidine on the Expression of Red Blood Cell Globin Genes in Myelodysplastic Syndromes. Blood, 115(13), 2615-2623.

[4] Reference to Side Effects is from DrugPatentWatch.com's AZACITIDINE (systemic) - Vidaza - Side Effects, Adverse Effects, and Toxicity - drugpatentwatch.com (#accessed 2024)